"INTERACTION OF BONE AND VASCULAR DISEASE IN

CKD-5"
Paolo Raggi.
Professor of Medicine. Section of Cardiology.
Tulane University Health Sciences Center. New Orleans, LA,
USA

praggi@tulane.edu
End stage renal disease is associated with hyperphosphatemia and hyperparathyroidism
that often results in soft-tissue calcification. Indeed, arterial calcification is particularly
common and associated in advanced renal failure stages (CKD-V). 1-4 Recent studies have
implicated the ingestion of calcium salts and/or the inevitable metabolic consequences of
this therapy such as elevated serum calcium, hypercalcemic episodes, or suppression of
parathyroid hormone as possible causative factors.3-7CKD patients are at high risk for
cardiovascular disease and suffer from sudden death or myocardial infarction with much
higher frequency than non-uremic individuals.
Though at entry in a dialysis program, most patients present a high burden of risk factors
such as hyperlipidemia, diabetes mellitus, and hypertension, cardiovascular disease in
CRF is explained by traditional risk factors only in part. 8
Indeed, recent evidence suggests that some of the risk may be associated with
abnormalities of mineral metabolism such as hyperphosphatemia and an elevated
calcium-phosphorus (Ca x P) product. 9. Though many patients with end-stage renal
disease (ESRD) are in positive calcium balance, their bone tissue is paradoxically unable
to handle the calcium load provided through calcium-based phosphate binders, dialysate
and diet. Indeed, uremic osteodystrophy comprises 2 forms of bone disease: low turnover
and high turnover bone disease. In the former state, bone is unable to handle calcium and
there is minimal accretion of this mineral in the bone tissue. 10 In high turnover bone
disease calcium is avidly absorbed by the bone but it is also rapidly removed. The endresult in either case is an excess availability of calcium in the circulation with the
possibility to develop metastatic calcification of cardiovascular tissues as well as other
soft tissues. Therefore, an effective control of serum phosphorus levels and Ca x P
product appears to be very important to potentially reduce cardiovascular risk and
improve bone health in CKD.

Pathogenesis of Cardiovascular Calcification in CKD

In patients affected by CKD-V the atherosclerotic plaques tend to be more extensive,
more calcified and progress more rapidly (do we have a reference for this more rapid
progression in ESRD?) than in age-matched non-uremic patients with known or

suspected coronary artery disease. 11 Coronary, aortic and valvular calcification occurs at
an early stage in CKD patients and even pediatric uremic subjects show extensive
vascualar calcifications.
In 1988, Rostand and colleagues examined 43 dialysis patients using energy subtraction
radiography to measure myocardial calcium content. They found that the dialysis patients
had significantly higher myocardial calcium content than control subjects The process of
vascular calcification is not entirely passive, as it is now believed to be an active process
of mineral deposition resembling bone formation that can be initiated and promoted by
hyperphosphatemia, hypercalcemia and hyperlipidemia. The combination of excess
calcium load and elevated phosphorus levels in CKD patients causes a rise in the Ca x P
product that may favor deposition of calcium in the soft tissues. It should be recognized
that calcium in the atherosclerotic plaque accumulates mainly in the sub-intimal space
and that CKD patients have an extensive plaque burden. However, extensive calcification
of the medial layers of the coronary arteries and aorta are also possible and likely
contribute to the extreme degree of calcification noted in this patient population.

The Investigative Tool

Electron beam computed tomography (EBCT) is a non-invasive radiological tool that can
be employed to perform an accurate assessment of the presence and extent of
calcification in the vasculature and cardiac valves. Quantification is performed by means
of a scoring method that takes into consideration the size and density of a calcified focus.
The calcification score measured by EBCT has been shown to correlate well with the
occurrence of adverse cardiac events and silent myocardial ischemia in non-uremic
subjects. 12 Similar data are also being accumulated in the CKD population. Finally,
sequential EBCT scanning has been employed to evaluate the effectiveness of therapeutic
strategies to slow the progression of coronary artery disease. 13-14

Sequential EBCT Studies in CKD 5 Patients

Chertow et al. recently evaluated 202 chronic hemodialysis patients using sequential
EBCT imaging in the context of an international randomized clinical trial. Patients were
randomized to treatment with one of 2 phosphate binders: a traditional calcium based salt
or sevelamer (Renagel) (Figure 1).15

At the end of the first 12 months

of follow-up, the calcium treated
patients showed a significant

progression of the calcification score of the aorta (median increase 28%) and coronary
arteries (median increase 25%), while the sevelamer (Renagel) treated patients showed
no change from baseline in either vascular territory (median increase 6% and 5%
respectively,Figure 2 and 3).

Seventy-three volunteers from the original cohort continued the study for 12 more
months of randomization (Figure 1).At the end of 24 months of follow-up, the
calcification progression in the aorta and coronary arteries had further magnified in
patients treated with calcium salts reaching highly statistically significant values (82%
and 61% increase, respectively; P<0.0001 from baseline). The patients treated with
sevelamer (Renagel) again showed no significant change from baseline (20% and 7%,
respectively, Figure 4).

In

view of the likely interaction of vascular and bone disease, in the extension trial the
investigators also conducted an analysis of the change in bone density of the thoracic
spine in the 2 treatment groups by means of CT densitometry. The patients treated with
calcium salts showed a significant loss in trabecular bone density (-7%) and a nonsignificant decrease in cortical bone density (-2%). On the contrary, patients treated with
sevelamer (Renagel) showed a significant increase in trabecular bone density (+5%)
and a non-statistically significant increase (+2%) in cortical bone density (Figure 5).

Conclusions
It has been suggested that inadequate management of calcium and phosphorus in CKD-V
is an independent predictor of cardiovascular morbidity and mortality in this patient
population. Both population based and CKD specific analyses point at an important
interaction between bone and vascular health. Changess in management in calcium and
phosphorus management directed to avoid directed at avoiding excess calcium load may
reduce the risk of disease progression in both fields. Efforts to maintain Strict a strict
control of the efforts to maintain serum phosphorus below 5.5 mg/dL, serum calcium
below 9.5 mg/dl and Ca x P product below 55 mg 2/dL2 have been recommended in an
attempt to reduce the risks of uremic calcification, cardiovascular disease, and cardiac
death. Sevelamer (Renagel), a calcium-free phosphate binder, provides an important
option for the management of dialysis patients at risk for cardiovascular calcification.

References:
1. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed
tomography in the evaluation of cardiac calcification in chronic dialysis
patients. Am J Kidney Dis 1996;27:394-401

2. Gurin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness

attenuation on survival of patients in end- stage renal
failure. Circulation 2001;103:987-992
3. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, et al. Advanced coronary
and carotid arteriopathy in young adults with childhood-onset chronic
renal failure. Circulation 2002;106:100-105
4. London G, Guerin AP, Marchais SJ et al. Arterial media calcification in
end stage renal disease: impact on all cause and cardiovascular mortality.
Nephrol Dial Transplant 2003;18:1731-40
5. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification
in young adults with end-stage renal disease who are undergoing
dialysis. N Engl J Med 2000;342:1478-1483
6. Gurin AP, London GM, Marchais SJ, Metvier F. Arterial stiffening and
vascular calcifications in end-stage renal disease. Nephrol Dial
Transplant 2000;15:1014-1021
7. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult
hemodialysis patients: a link between ESRD and cardiovascular disease?
J Am Coll Cardiol 2002;39:695-701
8. Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular risk
factors in dialysis patients compared with the general population: the
CHOICE study. J Am Soc Nephrol 2002;13:1918-27
9. Block, GA, Hulbert-Shearon, TE, Levin, NW, Port, FK Association of
serum phosphorus and calcium x phosphate product with mortality risk in
chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;
31: 607-17
10. Kurz P, Monier-Fuagere MC, Bognar B et al. Evidence for abnormal
calcium homeostasis in patients with adynamic bone disease. Kidney Int
1994;46:855-861
11. Schwarz, U, Buzello, M, Ritz, E, Stein, G, Raabe, G, Wiest, G, Mall, G,
Amann, K Morphology of coronary atherosclerotic lesions in patients with
end-stage renal failure. Nephrol Dial Transplant 2000;15: 218-23
12. Shaw L, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic
value of cardiac risk factors and coronary artery calcium screening for all
cause mortality. Radiology 2003;228:826-833
13. Callister, TQ, Raggi, P, Cooil, B, Lippolis, NJ, Russo, DJ Effect of HMGCoA reductase inhibitors on coronary artery disease as assessed by
electron-beam computed tomography. N Engl J Med 1998;339: 1972-8
14. Raggi, P Regression of calcified coronary artery plaque assessed by
electron beam computed tomography. Z Kardiol 2000;89: 135-9
15. Chertow, GM, Burke, SK, Raggi P. Sevelamer attenuates the progression
of coronary and aortic calcification in hemodialysis patients. Kidney
International 2002;62:245-252